UKHIFU - High Intensity Focused Ultrasound contact us  
Text Size: Small Text Medium Text Large Text








April 17, 2012
Lancet Oncology Study
Study shows significant side effect reduction with HIFU to treat prostate cancer... more >


Sky News, April 17, 2012
Prostate Cancer Treatment 'Reduces Side Effects'
A high-powered beam of ultrasound can destroy prostate cancer without causing the serious side effects... more >


Urology Times, May 1, 2012
Data show low morbidity of HIFU in short-term trials
Technique appears safe, but evaluation of efficacy awaits longer-term data... more >

Comparison of features offered by HIFU Devices

Device Features Sonablate® 500 Ablatherm®
Treatment Customisation
  • Completely customisable physician controlled power levels, with software recommendation
  • Treatment based on tissue response and proximity to vital structures such as rectal wall and neurovascular bundles
  • Limits physicians to only 3 pre-set power settings
  • Power settings are unchangeable once treatment has begun, not allowing physicians to adjust for changes in tissue density or tissue response
Imaging
  • Real-time neurovascular bundle blood flow detection
  • Real-time transverse and sagittal images
  • Real-time feedback of HIFU therapy with Sonablate Tissue Change Monitoring software (TCM). TCM quantifies tissue changes based on a comparison of radio frequency (RF) ultrasound pulse-echo signals at each treatment site. TCM calculates the change and, with color coding, displays it visually on-screen guiding physicians to the optimal delivery of HIFU energy
  • No real-time sagittal image
  • No real-time tissue change response feature
Lesion Size
  • 10-12mm
  • Greater precision for critical spaces around the prostate, enabling user to treat entire gland with 100% ablation and no spare tissue
  • 19-26mm
  • Ablatherm users must leave tissue untreated near external sphincter and neurovascular bundles, during nerve sparing procedures
  • Protocol states users must leave 4 mm “safety zone” untreated, potentially leaving cancer cells and viable PSA producing tissue behind
Prostate Size
  • Can treat up to a 40g prostate, without a transurethral resection of the prostate (TURP)
  • Can treat only up to a 30g prostate
  • Requires TURP for larger prostates

Portability

  • Mobile
  • Same footprint of a conventional ultrasound machine
  • Weighs 113 kg
  • Not portable, footprint of a surgical table plus an additional console
  • Weighs 431 kg
Patient Safety
  • By using reference and real time images the rectal wall is constantly monitored to determine any changes to its structure and changes to the treatment plan
  • Active cooling system circulates chilled water through the probe during the procedure to ensure patient safety
  • No monitoring of rectal wall condition against changes cause by the treatment or internal gland movement
  • Relies on external motion detection and refrigerated gel to keep temperatures low

Copyright © 2012 UKHIFU | All rights reserved